Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 11/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 3/20 | 0.40 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | ADH5 | P11766 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336517 | 0.82 | KMO (0.42) | KMOALDH1A1KRASADH5 | |
| SCHEMBL7539758 | 0.78 | ALDH1A1 (0.41) | KMOALDH1A1ADH5 | |
| SCHEMBL5009737 | 0.75 | KDM5C (0.46) | KMOALDH1A1 | |
| SCHEMBL2338601 | 0.73 | KMO (0.45) | KMOALDH1A1ADH5 | |
| SCHEMBL1935613 | 0.73 | KMO (0.48) | KMOALDH1A1ADH5PKM | |
| SCHEMBL10086351 | 0.73 | ALDH1A1 (0.56) | ALDH1A1ADH5 | |
| SCHEMBL352525 | 0.73 | LOXL2 (0.61) | LOXL2LOXLOXL3 | |
| SCHEMBL2335008 | 0.72 | KMO (0.44) | KMOALDH1A1ADH5 | |
| Hydrochloric Acid SCHEMBL1272214 | 0.72 | ALDH1A1 (0.55) | ALDH1A1ADH5DPP4 | |
| SCHEMBL2340435 | 0.71 | ALDH1A1 (0.42) | KMOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | LOXL2 3298/4885KMO 3132/4885ALDH1A1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.